The Aryl Hydrocarbon Receptor Ligand FICZ Improves Left Ventricular Remodeling and Cardiac Function at the Onset of Pressure Overload-Induced Heart Failure in Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 May 2022
Historique:
received: 27 04 2022
revised: 06 05 2022
accepted: 10 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

Adverse ventricular remodeling is the heart's response to damaging stimuli and is linked to heart failure and poor prognosis. Formyl-indolo [3,2-b] carbazole (FICZ) is an endogenous ligand for the aryl hydrocarbon receptor (AhR), through which it exerts pleiotropic effects including protection against inflammation, fibrosis, and oxidative stress. We evaluated the effect of AhR activation by FICZ on the adverse ventricular remodeling that occurs in the early phase of pressure overload in the murine heart induced by transverse aortic constriction (TAC). Cardiac structure and function were evaluated by cardiac magnetic resonance imaging (CMRI) before and 3 days after Sham or TAC surgery in mice treated with FICZ or with vehicle, and cardiac tissue was used for biochemical studies. CMRI analysis revealed that FICZ improved cardiac function and attenuated cardiac hypertrophy. These beneficial effects involved the inhibition of the hypertrophic calcineurin/NFAT pathway, transcriptional reduction in pro-fibrotic genes, and antioxidant effects mediated by the NRF2/NQO1 pathway. Overall, our findings provide new insight into the role of cardiac AhR signaling in the injured heart.

Identifiants

pubmed: 35628213
pii: ijms23105403
doi: 10.3390/ijms23105403
pmc: PMC9141655
pii:
doi:

Substances chimiques

6-formylindolo(3,2-b)carbazole 0
Carbazoles 0
Ligands 0
Receptors, Aryl Hydrocarbon 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Economy, Industry and Competitiveness
ID : SAF2017-84777-R
Organisme : Ministry of Science and Innovation (MCIN)/AEI/ 10.13039/501100011033 of Spain and the "European Union Next GenerationEU/PRTR
ID : PID2020-113238RB-I00
Organisme : Instituto de Salud Carlos III
ID : PI20/01482-1
Organisme : Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares
ID : CB16/11/00222
Organisme : Universidad Francisco de Vitoria
ID : Proyectos 2021

Références

Biomed Res Int. 2018 Jun 10;2018:6058784
pubmed: 29984241
Toxicol Appl Pharmacol. 2003 Dec 1;193(2):177-87
pubmed: 14644620
Stem Cells Int. 2016;2016:7943495
pubmed: 27829840
Cell Mol Life Sci. 2014 Feb;71(4):549-74
pubmed: 23649149
Basic Res Cardiol. 2019 Mar 18;114(3):19
pubmed: 30887214
Toxicol Sci. 2009 Oct;111(2):238-46
pubmed: 19474220
Circulation. 2021 Feb 9;143(6):566-580
pubmed: 33272024
J Mol Cell Cardiol. 2016 Aug;97:245-62
pubmed: 27262674
Pharmacol Res. 2020 Oct;160:105180
pubmed: 32877693
J Am Coll Cardiol. 2000 Mar 1;35(3):569-82
pubmed: 10716457
Biochem Biophys Res Commun. 2004 Oct 1;322(4):1178-91
pubmed: 15336966
Br J Pharmacol. 2010 Aug;160(7):1573-6
pubmed: 20649560
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):316-31
pubmed: 15364547
Vet Pathol. 1997 Nov;34(6):605-14
pubmed: 9396142
J Biol Chem. 1992 Dec 5;267(34):24591-5
pubmed: 1447203
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8185-9
pubmed: 1325649
Sci Total Environ. 2020 Jun 1;719:135097
pubmed: 31837856
Pharmacol Rev. 2013 Aug 01;65(4):1148-61
pubmed: 23908379
J Biol Chem. 1987 Nov 15;262(32):15422-7
pubmed: 2824460
Cardiovasc Toxicol. 2002;2(4):263-74
pubmed: 12665660
Drug Metab Rev. 2006;38(3):411-50
pubmed: 16877260
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Cell Commun Signal. 2014 Sep 21;12:57
pubmed: 25238970
Sci Rep. 2020 May 21;10(1):8477
pubmed: 32439897
JACC Cardiovasc Imaging. 2011 Jan;4(1):98-108
pubmed: 21232712
J Exp Med. 2018 Aug 6;215(8):2197-2209
pubmed: 29934320
N Engl J Med. 1990 May 31;322(22):1561-6
pubmed: 2139921
Biochem J. 2014 Mar 1;458(2):187-93
pubmed: 24524191
Mol Pharmacol. 1993 Nov;44(5):911-7
pubmed: 8246913
J Dermatol Sci. 2018 Jan;89(1):19-26
pubmed: 29102224
Pharmacol Res. 2021 Jan;163:105316
pubmed: 33248198
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Pharmacol Ther. 2018 May;185:50-63
pubmed: 29258844
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Br J Pharmacol. 2009 Dec;158(7):1808-19
pubmed: 19889059
Arch Toxicol. 2014 Mar;88(3):725-38
pubmed: 24247421
Biochem Biophys Res Commun. 1992 Apr 15;184(1):246-53
pubmed: 1314586
Am J Hypertens. 2019 Jan 1;32(1):34-44
pubmed: 30329020
Toxicol Appl Pharmacol. 2004 Jan 1;194(1):79-89
pubmed: 14728982
Circ Res. 2000 Dec 8;87(12):E61-8
pubmed: 11110780
Eur J Immunol. 2016 Apr;46(4):1047-57
pubmed: 26786786
Nat Rev Cardiol. 2018 Feb;15(2):83-96
pubmed: 28933783
Free Radic Biol Med. 2007 Jul 15;43(2):271-81
pubmed: 17603936
Histochem Cell Biol. 2009 Apr;131(4):471-81
pubmed: 19030868
Br J Pharmacol. 2020 Jul;177(14):3273-3290
pubmed: 32154912
Toxicol Lett. 2015 Apr 16;234(2):74-80
pubmed: 25680693

Auteurs

María Tamayo (M)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Laura Martín-Nunes (L)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

María José Piedras (MJ)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
Facultad de Medicina, Universidad Francisco de Vitoria (UFV), 28223 Madrid, Spain.

María Martin-Calvo (M)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Daniel Martí-Morente (D)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Marta Gil-Fernández (M)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain.

Nieves Gómez-Hurtado (N)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

María Ángeles Moro (MÁ)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.

Lisardo Bosca (L)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

María Fernández-Velasco (M)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain.

Carmen Delgado (C)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH